CMS's 2021 ESRD PPS, AKI, and QIP Proposed Rule Webinar

When:  Aug 6, 2020 from 2:00 PM to 3:00 PM (ET)
Associated with  Open Member Community
This important webinar will review the changes in the CMS 2021 ESRD PPS, AKI, and QIP Proposed Rule issued on July 7, 2020. Our Legislative Counsel will review the changes and their impact to dialysis facilities, including:

  • CY2021 ESRD Prospective Payment System (PPS)
  • CY 2021 Acute Kidney Injury (AKI)
  • PYs 2023 and 2024 ESRD Quality Incentive Program (QIP)
The proposed rule proposes one key policy priority directly advocated for by the NRAA in response to the COVID-19 public health emergency (PHE), which would hold harmless those facilities that otherwise would be eligible for the low-volume payment adjustment (LVPA) in 2021, 2022, and 2023 but lose their status due to treatment of a higher-than-expected number of patients during the pandemic. Read the full Proposed Rule Summary here.

Exclusively available to NRAA Members!

Presented by:

Lauren Aronson
Partner, Mehlman Castagnetti Rosen & Thomas

Lauren Aronson is a health policy expert and serves as a partner at Mehlman Castagnetti Rosen & Thomas, a bipartisan lobbying firm in Washington, DC. Prior to joining the firm, Aronson spent three years at the Centers for Medicare and Medicaid Services (CMS), where she directed the Office of Legislation and led the Agency’s interactions with Capitol Hill. Before joining CMS, Aronson served as a Professional Staff Member for the House Ways and Means Committee, working on Medicare Advantage and Medicare Part D payment policies.

Aronson served in the White House under President Obama as the Policy Director in the Office of Health Reform. She was a key member of the Administration’s team working to enact the Affordable Care Act, President Obama’s signature health care law.

Kara Cardinale
Founder & Principal, Kasper Cardinale Consulting

Kara Cardinale serves as founder and principal of Kasper Cardinale Consulting, LLC, an independent health policy consultancy that provides strategic advice and analysis to clients on regulatory and legislative actions impacting the health care industry, including recent actions by the U.S. Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) to advance the treatment of kidney disease across the U.S. Previously,

Kara served as a senior Medicare program examiner at the White House Office of Management and Budget (OMB) during enactment of the Affordable Care Act of 2010 (ACA) and implementation of the Medicare Modernization Act of 2003 (MMA). Kara earned her Bachelor of Arts in philosophy from Haverford College and a Master of Public Policy from the University of Texas at Austin.